Qbic has participated in a $32.8m funding round for EyeD, consisting of $9.4m in equity and another $23.4m in debt financing and government grants.
EyeD, a Belgium-based developer of an implant to treat glaucoma that was spun out of the University Hospital of Liège (CHU Liège), has raised a total of €28m ($32.8m) from investors including multi-university venture fund Qbic.
Qbic participated in an $9.4m equity tranche together with Fund+ and assorted private investors. The remaining $23.4m came in the form of bank loans and grant financing from the Walloon government, though further details were not disclosed.
Founded in 2012, EyeD has developed an eye implant that is less than one centimetre in diameter and is inserted into the eye through a small incision in a surgical procedure that takes ten minutes.
The implant contains the sane ingredients as eye drops that are currently used to treat glaucoma, and discharges the drug over three years. EyeD hopes the approach will help patients who have struggled to administer daily drops, which can…
Thierry Heles
Thierry Heles is the editor of Global University Venturing, host of the Beyond the Breakthrough interview podcast and responsible for the monthly GUV Gazette (sign up here for free).
